IN2014KN01714A - - Google Patents

Info

Publication number
IN2014KN01714A
IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01714A publication Critical patent/IN2014KN01714A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1714KON2014 2012-02-21 2013-02-21 IN2014KN01714A (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035342 2012-02-21
PCT/JP2013/054312 WO2013125630A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
IN2014KN01714A true IN2014KN01714A (tr) 2015-10-23

Family

ID=49005808

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1714KON2014 IN2014KN01714A (tr) 2012-02-21 2013-02-21

Country Status (17)

Country Link
US (1) US9260513B2 (tr)
EP (1) EP2818481B1 (tr)
JP (1) JP6187257B2 (tr)
KR (1) KR102005308B1 (tr)
CN (1) CN104114581B (tr)
AU (1) AU2013223137B2 (tr)
BR (1) BR112014021099A2 (tr)
CA (1) CA2864999C (tr)
DK (1) DK2818481T3 (tr)
ES (1) ES2749672T3 (tr)
HU (1) HUE046788T2 (tr)
IN (1) IN2014KN01714A (tr)
MX (1) MX363136B (tr)
PL (1) PL2818481T3 (tr)
PT (1) PT2818481T (tr)
RU (1) RU2639522C2 (tr)
WO (1) WO2013125630A1 (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
CN106039307A (zh) * 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
KR101805520B1 (ko) * 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PL2740489T3 (pl) * 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
IN2014KN01715A (tr) 2012-02-21 2015-10-23 Toray Industries
MX358224B (es) * 2012-03-30 2018-08-10 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
HUE036425T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
RU2646464C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
RU2678138C2 (ru) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2017348734A1 (en) 2016-10-28 2019-05-16 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3095719A1 (en) 2018-03-30 2019-10-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20200390899A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
WO2021067242A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
WO2021182574A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
JPWO2021182572A1 (tr) 2020-03-12 2021-09-16
BR112022018166A2 (pt) * 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CN116234586A (zh) 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
WO2022270523A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
CA3225422A1 (en) 2021-06-23 2022-12-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378476A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022316644A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3234604A1 (en) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
HUP0101160A2 (hu) 1998-04-03 2001-08-28 Chugai Seiyaku Kabushiki Kaisha Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1870466A3 (en) 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004526401A (ja) 2000-03-29 2004-09-02 コリクサ コーポレイション 肺癌の治療および診断のための組成物および方法
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US7476536B2 (en) 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
US20050202451A1 (en) 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
EP1735348B1 (en) 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
PT1730191E (pt) 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
ZA200706017B (en) 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
AU2006223374B2 (en) 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
UA127472C2 (uk) 2008-03-18 2023-09-06 Дженентек, Інк. Комбінація кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичного засобу і спосіб застосування
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
AU2009278385B2 (en) 2008-08-05 2015-06-11 Toray Industries, Inc. Immunity-inducing agent
CN106039307A (zh) 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
WO2011020529A2 (en) 2009-08-19 2011-02-24 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
MY160680A (en) 2009-09-22 2017-03-15 Probiogen Ag Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
AU2011211700B2 (en) 2010-02-04 2015-06-11 Toray Industries, Inc. Medicament for treating and/or preventing cancer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2011096528A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2532680T3 (pl) 2010-02-04 2015-10-30 Toray Industries Kompozycja medyczna do leczenia raka i/lub zapobiegania
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
EA028515B1 (ru) 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
JP5545105B2 (ja) 2010-08-04 2014-07-09 株式会社ジェイテクト トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置
PL2740489T3 (pl) 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
PL3351630T3 (pl) 2011-08-04 2020-05-18 Toray Industries, Inc. Kompozycja farmaceutyczna zawierająca przeciwciała przeciwko CAPRIN-1 do leczenia nowotworu i/lub zapobiegania nowotworowi
US9796775B2 (en) * 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
HUE036425T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére
MX358224B (es) 2012-03-30 2018-08-10 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.

Also Published As

Publication number Publication date
PT2818481T (pt) 2019-10-25
CN104114581B (zh) 2018-11-30
JP6187257B2 (ja) 2017-08-30
HUE046788T2 (hu) 2020-03-30
JPWO2013125630A1 (ja) 2015-07-30
EP2818481A1 (en) 2014-12-31
DK2818481T3 (da) 2019-10-14
KR102005308B1 (ko) 2019-07-30
AU2013223137A1 (en) 2014-09-11
ES2749672T3 (es) 2020-03-23
US9260513B2 (en) 2016-02-16
EP2818481A4 (en) 2015-10-07
PL2818481T3 (pl) 2020-02-28
EP2818481B1 (en) 2019-08-07
CN104114581A (zh) 2014-10-22
KR20140130670A (ko) 2014-11-11
RU2639522C2 (ru) 2017-12-21
MX363136B (es) 2019-03-12
US20150044221A1 (en) 2015-02-12
RU2014138039A (ru) 2016-04-10
CA2864999A1 (en) 2013-08-29
MX2014009747A (es) 2014-11-14
BR112014021099A2 (pt) 2020-12-01
CA2864999C (en) 2020-06-30
WO2013125630A1 (ja) 2013-08-29
AU2013223137B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
IN2014KN01713A (tr)
IN2014KN01714A (tr)
IN2014KN01716A (tr)
IN2014KN01715A (tr)
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360671B (es) Composición farmacéutica para el tratamiento y/o prevención del cáncer.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
MY167232A (en) Polypeptides binding to human complement c5
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
IN2014DN09963A (tr)
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
WO2014039074A3 (en) Therapeutic compositions and related methods
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.